4月18日，美年健康今日收盘5.19元，下跌2.08%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到71.98倍，总市值203.15亿元。 从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均45.89倍，行业中值48.60倍，美年健康排 名第33位。 股东方面，截至2025年3月31日，美年健康股东户数189346户，较上次增加72947户，户均持股市值 35.28万元，户均持股数量2.76万股。 美年大健康产业控股股份有限公司的主营业务是健康体检服务。公司的主要产品是体检服务。 最新一期业绩显示，2024年年报，公司实现营业收入107.02亿元，同比-1.76%；净利润2.82亿元，同 比-44.18%，销售毛利率42.78%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)33美年健康71.9871.982.57203.15亿行业平均 45.8942.243.37142.32亿行业中值48.6037.502.4250.67亿1普瑞眼科-182.9122.862.7661.25亿2何氏眼 科-147.3745.181.4828.71亿3迪安诊断-92.4427.831.2185. ...

Core Insights - The health management revolution driven by AI is gradually unfolding in the consumer market, with Meinian Health leveraging vast health data and a nationwide network of health examination centers to capture a significant share of the market [1][9] - In 2024, Meinian Health reported a revenue of 10.702 billion yuan and a net profit of 283 million yuan, with over 215 million yuan of revenue generated from AI-related services [1][7] - The aging population and increasing health concerns among the elderly are creating a robust demand for health management services, with the overall health management market expected to exceed 3 trillion yuan by 2028 [2][3] Market Dynamics - The rapid aging of the population in China, with over 310 million elderly individuals and a chronic disease prevalence rate exceeding 78%, is driving demand for health management services [2][3] - The introduction of new health screening products, such as "Nai Rui Jia" for brain health and "Fei Jie Ning" for lung health, reflects the growing consumer willingness to pay for personalized health management services [2][3] Policy Support - Recent government policies, including the "Promotion of Health Consumption Special Action Plan," are accelerating the development of AI-driven health management services, encouraging health examination institutions to extend their services [3][9] - The government's focus on "AI + healthcare" as a key area for innovation highlights the importance of technology in addressing healthcare challenges, particularly for the elderly [3][9] Data and Technology - Meinian Health possesses a significant data advantage, with over 1 billion imaging data points and more than 200 million structured health data points, establishing the largest personal health examination data center in China [4][6] - The integration of AI into health management services is enhancing the precision of health risk predictions and management, exemplified by the AI-driven blood sugar management product that utilizes a "three-expert management" model [4][5] Business Model Innovation - The convergence of data assets and health management scenarios is creating a "snowball effect," where increased data leads to improved AI capabilities and service precision [5][6] - Meinian Health is redefining its business model by creating a digital health service platform that integrates health examinations, intelligent diagnostics, specialized treatments, and insurance payments [6][10] Future Outlook - The company is set to further promote its AI health management assistant "Health Xiao Mei" across its examination centers, enhancing its capabilities in personalized health risk assessment and management [8][10] - The ongoing development of smart wearable devices and digital therapies will contribute to a new model of health management, driven by AI and aimed at chronic disease management [8][10]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a total revenue of 10.702 billion yuan in 2024, a year-on-year decrease of 1.76%, while the net profit attributable to shareholders was 282.24 million yuan, down 44.18% year-on-year [7] - AI revenue is beginning to scale, with 215.58 million yuan generated from AI-related services, including heart-lung screening and AI for eye and brain health [7] - The company has a stable increase in customer unit price, with an average price of 672 yuan for health check-ups in 2024, reflecting a 4.1 percentage point increase in individual check-up revenue share [7] - The acquisition of 19 health examination centers is expected to enhance the company's performance, contributing approximately 505 million yuan in total revenue and 52 million yuan in net profit for 2024 [7] - The profit forecast for 2025-2026 has been adjusted to 629.21 million yuan and 911.79 million yuan respectively, with a projected net profit of 1.125 billion yuan in 2027, corresponding to PE valuations of 33, 23, and 18 times [7] Summary by Sections Financial Performance - Total revenue for 2024 is projected at 10.702 billion yuan, with a year-on-year growth rate of -1.76% [1] - Net profit attributable to shareholders is expected to be 282.24 million yuan, reflecting a decline of 44.18% year-on-year [1] - The company anticipates a gradual recovery in revenue growth, with projections of 11.587 billion yuan in 2025 and 12.432 billion yuan in 2026 [8] AI and Data Utilization - The company has leveraged its extensive health data, with over 1 billion imaging data points and 200 million structured health data points, to integrate AI technology into its services [7] - The introduction of AI-driven health management tools is expected to reduce service costs and enhance operational efficiency [7] Market Position and Expansion - The company operates 576 health examination centers, with a mix of wholly-owned and joint-venture facilities [7] - The acquisition of additional centers is aimed at solidifying market position and supporting the implementation of AI strategies [7]

Performance Summary - In 2024, the company reported a revenue of 10.702 billion yuan, a year-on-year decrease of 1.76% [1] - The net profit attributable to shareholders was 282 million yuan, down 44.18% year-on-year [1] - The non-recurring net profit attributable to shareholders was 252 million yuan, a decline of 45.52% year-on-year [1] - For Q4 2024, the company achieved a revenue of 3.561 billion yuan, a decrease of 3.12% year-on-year [1] - The net profit attributable to shareholders for Q4 was 258 million yuan, down 8.01% year-on-year [1] - The non-recurring net profit attributable to shareholders for Q4 was 244 million yuan, an increase of 3.76% year-on-year [1] Operational Analysis - The company is deepening the value of its healthcare big data assets and fully implementing the "All in AI" strategy, generating 212 million yuan in revenue from AI technology in 2024 [2] - The company launched the first AI digital health management assistant "Health Xiaomei" in collaboration with Huawei, which began trial operations in 2024 [2] - New innovative products include AI smart blood glucose management, AI smart liver health management, and others, enhancing market competitiveness [2] - The company's data resources are being utilized in various scenarios, with data assets valued at 8.82 million yuan included in intangible assets [2] Branch Expansion and Customer Metrics - By the end of 2024, the company had a total of 576 branches, including 312 controlling health examination branches [3] - The company served 25.25 million customers in 2024, with 15.38 million from controlling branches [3] - The revenue distribution from group and individual clients was 75.9% and 24.1%, respectively [3] - The average customer price for health examinations was 672 yuan, showing a stable increase from 653 yuan in the first half of 2024 [3] Profit Forecast and Valuation - The company has adjusted its profit forecast for 2025-2026, expecting net profits of 607 million yuan, 748 million yuan, and 886 million yuan for 2025-2027, respectively [4] - The earnings per share (EPS) are projected to be 0.16 yuan, 0.19 yuan, and 0.23 yuan for the same period [4] - The current price corresponds to a price-to-earnings (PE) ratio of 34, 28, and 24 for 2025-2027 [4] - The company maintains a "buy" rating despite the adjustments [4]

证券代码：002044 证券简称：美年健康 公告编号：2025-018 美年大健康产业控股股份有限公司 关于 2023 年股票期权激励计划首次授予的股票期权 第一个行权期行权条件未成就及注销部分股票期权的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 美年大健康产业控股股份有限公司（以下简称"公司"、"美年健康"）于 2025 年 4 月 15 日召开第九届董事会第八次会议、第八届监事会第二十九次会议，审 议通过《关于 2023 年股票期权激励计划首次授予的股票期权第一个行权期行权 条件未成就及注销部分股票期权的议案》。现将有关事项说明如下： 一、本激励计划已履行的决策程序和批准情况 1、2023 年 12 月 6 日，公司召开第八届董事会第三十次（临时）会议，审议 通过了《关于公司<2023 年股票期权激励计划（草案）>及其摘要的议案》、《关 于公司<2023 年股票期权激励计划实施考核管理办法>的议案》及《关于提请股 东大会授权董事会办理公司 2023 年股票期权激励计划相关事项的议案》等议案。 同日，公司召开第八届监事会第十八次（临时）会议，审议通 ...

北京市天元律师事务所 关于美年大健康产业控股股份有限公司 2023 年股票期权激励计划 首次授予的股票期权第一个行权期行权条件未成就 及注销部分股票期权的法律意见 北京市天元律师事务所 北京市西城区金融大街 35 号 国际企业大厦 A 座 509 单元 邮编：100033 北京市天元律师事务所 关于美年大健康产业控股股份有限公司 2023 年股票期权激励计划 首次授予的股票期权第一个行权期行权条件未成就 及注销部分股票期权的法律意见 京天股字（2023）第 617-4 号 致：美年大健康产业控股股份有限公司 北京市天元律师事务所（以下简称"本所"）接受美年大健康产业控股股份有限 公司（以下简称"美年健康"或"公司"）的委托，担任公司 2023 年股票期权激励计 划（以下简称"本次激励计划"）的专项法律顾问，为公司本次激励计划首次授予的 股票期权第一个行权期行权条件未成就及注销部分股票期权（以下简称"本次激励 计划行权条件未成就及注销事项"）出具本法律意见。 本所对公司提供的、本所认为出具本法律意见所需的文件进行了法律审查，就 公司股权激励计划的本次激励计划行权条件未成就及注销事项以及与之相关的问 题向相关人员 ...

关于美年大健康产业控股股份有限公司 非经营性资金占用及 其他关联资金往来情况 汇总表的专项审核报告 众环专字(2025)0203805号 目 录 起始页码 专项审核报告 汇总表 非经营性资金占用及其他关联资金往来的情况汇总表 1 关于美年大健康产业控股股份有限公司 非经营性资金占用及其他关联资金往来情况汇总表 的专项审核报告 众环专字(2025)0203805 号 美年大健康产业控股股份有限公司全体股东： 我们接受委托，在审计了美年大健康产业控股股份有限公司（以下简称"美年健康"） 2024 年 12 月 31 日合并及公司的资产负债表，2024 年度合并及公司的利润表、合并及公司 的现金流量表和合并及公司的股东权益变动表以及财务报表附注的基础上，对后附的《上市 公司 2024 年度非经营性资金占用及其他关联资金往来的情况汇总表》（以下简称"汇总表"） 进行了专项审核。按照中国证券监督管理委员会印发的《上市公司监管指引第 8 号——上市 公司资金往来、对外担保的监管要求》的规定，编制和披露汇总表、提供真实、合法、完整 的审核证据是美年健康管理层的责任，我们的责任是在执行审核工作的基础上对汇总表发表 专项审核意 ...

粤开证券股份有限公司 关于美年大健康产业控股股份有限公司 2024 年度募集资金存放与使用情况的专项核查意见 粤开证券股份有限公司（以下简称"粤开证券"或"持续督导机构"）作为 美年大健康产业控股股份有限公司（以下简称"美年健康"、"上市公司"或"公 司"）2019 年度非公开发行股票的持续督导机构，根据《证券发行上市保荐业务 管理办法》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管 要求》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运 作》等相关法律、法规的规定，对美年健康 2024 年度募集资金存放与使用情况 进行了核查，核查情况及核查意见如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证监会《关于核准美年大健康产业控股股份有限公司非公开发行股票 的批复》（证监许可[2019]1556 号）核准，本公司采用非公开发行方式发行人民 币普通股（A 股）177,139,393 股，发行价格为 11.55 元/股，募集资金总额为人民 币 2,045,959,989.15 元，扣除本次发行费用人民币 40,488,318.39 元，实际募集资 金净额 ...

美年大健康产业控股股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审计了美 年大健康产业控股股份有限公司（以下简称"美年健康"）2024 年 12 月 31 日的财务报告内 部控制的有效性。 一、美年健康对内部控制的责任 美年大健康产业控股股份有限公司 内部控制审计报告 众环审字(2025)0204385号 内部控制审计报告 众环审字(2025)0204385 号 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指引》 的规定，建立健全和有效实施内部控制，并评价其有效性是美年健康董事会的责任。 如美年健康董事会 2024 年度财务报告内部控制评价报告所述，美年健康于 2024 年收购 淮北美年大健康管理有限公司、许昌美年大健康健康管理有限公司、益阳美年大健康健康管 理有限公司、常德美年大健康管理有限公司、娄底美年健康管理有限公司、南昌倍邦健康体 检中心有限公司、江西东湖倍康中西医结合门诊部有限公司、济南市莱芜美年大健康体检管 理有限公司、济南美年大健康科技有限公司、遂宁美慈体检医院有限公司、杭州美新医疗门 诊部有限公司、宁波北仑美年综合门诊 ...